Cargando…
Characteristics of Early Phase Clinical Trials for Rare Cancers: Insights From Interviews With Stakeholders
Background: Rare cancers occur with an incidence of no more than six cases per 100,000 people according to the definition used by the Surveillance of Rare Cancers in Europe project. For a variety of reasons (low prevalence, cytotoxicity), it is challenging to perform the necessary clinical studies t...
Autores principales: | Dooms, M, Saesen, R, Steemans, I, Lansens, J, Huys, I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108391/ https://www.ncbi.nlm.nih.gov/pubmed/35586057 http://dx.doi.org/10.3389/fphar.2022.775217 |
Ejemplares similares
-
Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making
por: Saesen, Robbe, et al.
Publicado: (2020) -
How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer
por: Saesen, Robbe, et al.
Publicado: (2022) -
Real-world data in oncology: a questionnaire-based analysis of the academic research landscape examining the policies and experiences of the cancer cooperative groups
por: Saesen, R., et al.
Publicado: (2023) -
Analysis of the characteristics and the degree of pragmatism exhibited by pragmatic-labelled trials of antineoplastic treatments
por: Saesen, Robbe, et al.
Publicado: (2023) -
Editorial: Prevention, diagnosis and treatment of rare disorders
por: Cox, Timothy M., et al.
Publicado: (2022)